Peter Nash

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.6K citations · Full text

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Laura C. Coates, Arthur Kavanaugh, Philip J. Mease et al. · Arthritis & Rheumatology · 2016 · 899 citations · Full text

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Philip J. Mease, Iain B. McInnes, Bruce Kirkham et al. · New England Journal of Medicine · 2015 · 723 citations · Full text

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

L.B.A. van de Putte, Michel Malaise, J Sany et al. · Annals of the Rheumatic Diseases · 2004 · 617 citations · Full text

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann et al. · Arthritis & Rheumatism · 2013 · 572 citations